Luminex Company Profile (NASDAQ:LMNX)

About Luminex (NASDAQ:LMNX)

Luminex logoLuminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company's products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments. The Company has a range of instruments using its xMAP technology, which includes its LUMINEX 100/200 systems offer 100-plex testing; the Company's FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to a range of testing laboratories.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: Life Sciences Tools & Services
  • Symbol: NASDAQ:LMNX
  • CUSIP: 55027E10
  • Web:
  • Market Cap: $890.82 million
  • Outstanding Shares: 43,926,000
Average Prices:
  • 50 Day Moving Avg: $19.48
  • 200 Day Moving Avg: $19.54
  • 52 Week Range: $17.64 - $23.75
  • Trailing P/E Ratio: 62.98
  • Foreward P/E Ratio: 32.71
  • P/E Growth: 0.72
Sales & Book Value:
  • Annual Revenue: $285.44 million
  • Price / Sales: 3.12
  • Book Value: $9.51 per share
  • Price / Book: 2.13
  • Dividend Yield: 1.2%
  • EBIDTA: $50.46 million
  • Net Margins: 5.10%
  • Return on Equity: 5.53%
  • Return on Assets: 5.04%
  • Current Ratio: 4.32%
  • Quick Ratio: 3.31%
  • Average Volume: 246,211 shs.
  • Beta: 0.59
  • Short Ratio: 10.02

Frequently Asked Questions for Luminex (NASDAQ:LMNX)

What is Luminex's stock symbol?

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

How often does Luminex pay dividends? What is the dividend yield for Luminex?

Luminex declared a special dividend on Wednesday, February 22nd. Shareholders of record on Friday, March 24th will be paid a dividend of $0.06 per share on Friday, April 14th. The ex-dividend date is Wednesday, March 22nd. View Luminex's Dividend History.

How were Luminex's earnings last quarter?

Luminex Co. (NASDAQ:LMNX) announced its quarterly earnings data on Monday, May, 1st. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.16 by $0.12. The firm earned $77.80 million during the quarter, compared to analyst estimates of $74.25 million. Luminex had a return on equity of 5.53% and a net margin of 5.10%. The business's quarterly revenue was up 23.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.29 EPS. View Luminex's Earnings History.

Where is Luminex's stock going? Where will Luminex's stock price be in 2017?

7 brokers have issued 12 month price targets for Luminex's shares. Their predictions range from $18.00 to $27.00. On average, they anticipate Luminex's stock price to reach $21.40 in the next twelve months. View Analyst Ratings for Luminex.

What are analysts saying about Luminex stock?

Here are some recent quotes from research analysts about Luminex stock:

  • 1. According to Zacks Investment Research, "Over the past one year, Luminex outperformed the broader industry in terms of price performance. The company operates in a highly competitive life sciences industry, which is likely to mar its growth trajectory in the coming quarters. Reduced spending on research and diagnostics by Luminex’ partner companies are adversely impacting the demand for the company’s products of late. Luminex may be impacted by future changes to the reimbursement landscape in the molecular diagnostic market. Luminex reported stable first-quarter 2017 results, beating the Zacks Consensus Estimates on both lines. Onthe positive side, the company’s Assay business will be its key growth driver over the long term. We are also optimistic about the company’s products – ARIES and NxTAG RPP – which represent a major revenue opportunity." (5/4/2017)
  • 2. Piper Jaffray Companies analysts commented, "Luminex announced 4Q16 revenue of $72.3M, in line with preliminary results. Adj. EPS of $0.06 missed the Street's $0.13 estimate. Results in the quarter reflect strong consumables growth, somewhat offset by lighter instrument sales. Management reaffirmed FY17 revenue guidance of $295M-$305M and provided 1Q17 revenue guidance in line with the Street ($73M-$75M; Street: $74.2M). Revenue guidance appears achievable, but we believe shares are fairly valued. We remain Neutral with a $19 price target (was $20) based on ~2.1x FY18 EV/Rev (unchanged) on our revised estimates." (2/7/2017)

Who are some of Luminex's key competitors?

Who owns Luminex stock?

Luminex's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.36%), VILLERE ST DENIS J & COMPANY LLC (8.93%), Villere ST Denis J & Co. LLC (9.31%), Vanguard Group Inc. (8.42%), RGM Capital LLC (6.63%) and Dimensional Fund Advisors LP (4.20%). Company insiders that own Luminex stock include G Walter Loewenbaum II, Harriss T Currie, Kevin M Mcnamara, Nachum Shamir and Russell W Bradley. View Institutional Ownership Trends for Luminex.

Who sold Luminex stock? Who is selling Luminex stock?

Luminex's stock was sold by a variety of institutional investors in the last quarter, including Kalmar Investments Inc. DE, Acadian Asset Management LLC, Great Lakes Advisors LLC, American Century Companies Inc., Bank of Montreal Can, Wells Fargo & Company MN, Eos Focused Equity Management L.P. and Russell Investments Group Ltd.. Company insiders that have sold Luminex stock in the last year include G Walter Loewenbaum II and Kevin M Mcnamara. View Insider Buying and Selling for Luminex.

Who bought Luminex stock? Who is buying Luminex stock?

Luminex's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., RGM Capital LLC, Elk Creek Partners LLC, Renaissance Technologies LLC, Blair William & Co. IL, Vanguard Group Inc., State Street Corp and Neuberger Berman Group LLC. Company insiders that have bought Luminex stock in the last two years include G Walter Loewenbaum II, Harriss T Currie and Nachum Shamir. View Insider Buying and Selling for Luminex.

How do I buy Luminex stock?

Shares of Luminex can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Luminex stock cost?

One share of Luminex stock can currently be purchased for approximately $20.28.

Analyst Ratings

Consensus Ratings for Luminex (NASDAQ:LMNX) (?)
Ratings Breakdown: 1 Sell Rating, 5 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $21.40 (5.52% upside)

Analysts' Ratings History for Luminex (NASDAQ:LMNX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/11/2017ValuEngineUpgradeSell -> HoldLowView Rating Details
5/2/2017Jefferies Group LLCBoost Price TargetHold$20.00 -> $21.00MediumView Rating Details
2/7/2017Piper Jaffray CompaniesLower Price TargetNeutral$20.00 -> $19.00N/AView Rating Details
2/7/2017William BlairReiterated RatingMarket PerformN/AView Rating Details
1/18/2017Deutsche Bank AGReiterated RatingSell$18.00N/AView Rating Details
10/12/2016Avondale PartnersInitiated CoverageOutperform$27.00N/AView Rating Details
8/18/2016JPMorgan Chase & Co.UpgradeUnderweight -> Neutral$18.00 -> $22.00N/AView Rating Details
5/3/2016Leerink SwannReiterated RatingHold$22.00N/AView Rating Details
8/4/2015WedbushUpgradeNeutral -> Outperform$19.00 -> $22.00N/AView Rating Details
7/1/2015Cowen and CompanyBoost Price TargetMarket Perform$17.00 -> $18.00N/AView Rating Details
(Data available from 5/23/2015 forward)


Earnings History for Luminex (NASDAQ:LMNX)
Earnings by Quarter for Luminex (NASDAQ:LMNX)
Earnings History by Quarter for Luminex (NASDAQ:LMNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2017Q1 2017$0.16$0.28$74.25 million$77.80 millionViewListenView Earnings Details
2/6/2017Q4 2016$0.09$0.11$70.92 million$72.30 millionViewListenView Earnings Details
10/31/2016Q316$0.12$0.21$68.90 million$71.20 millionViewListenView Earnings Details
7/28/2016Q216$0.18$0.33$61.20 million$64.20 millionViewListenView Earnings Details
5/2/2016Q116$0.14$0.29$60.98 million$63.00 millionViewListenView Earnings Details
11/2/2015Q315$0.11$0.17$57.24 million$60.60 millionViewListenView Earnings Details
8/3/2015Q215$0.12$0.27$57.01 million$58.90 millionViewListenView Earnings Details
5/4/2015Q115$0.12$0.23$56.50 million$57.70 millionViewListenView Earnings Details
2/2/2015Q414$0.12$0.19$58.31 million$58.10 millionViewListenView Earnings Details
10/27/2014Q314$0.10$0.27$56.60 million$56.68 millionViewListenView Earnings Details
7/28/2014Q214$0.10$0.20$55.90 million$55.50 millionViewListenView Earnings Details
4/28/2014Q114$0.12$0.24$55.31 million$56.60 millionViewListenView Earnings Details
2/3/2014Q413$0.07$0.21$56.63 million$55.20 millionViewListenView Earnings Details
11/4/2013Q313$0.11$0.02$54.67 million$50.80 millionViewListenView Earnings Details
7/29/2013Q2 2013$0.10$0.17$54.16 million$54.30 millionViewListenView Earnings Details
4/29/2013Q1 2013$0.08$0.19$51.94 million$53.20 millionViewListenView Earnings Details
2/4/2013Q4 2012$0.08$0.12$54.09 million$55.53 millionViewListenView Earnings Details
10/29/2012Q312$0.06$0.04$51.26 million$50.00 millionViewN/AView Earnings Details
7/30/2012$0.08$0.07ViewN/AView Earnings Details
4/30/2012$0.09$0.08ViewN/AView Earnings Details
2/6/2012$0.07$0.11ViewN/AView Earnings Details
11/1/2011$0.05$0.05ViewN/AView Earnings Details
8/8/2011$0.06$0.11ViewN/AView Earnings Details
5/9/2011$0.06$0.11ViewN/AView Earnings Details
2/7/2011$0.05$0.07ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Luminex (NASDAQ:LMNX)
2017 EPS Consensus Estimate: $0.24
2018 EPS Consensus Estimate: $0.45
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.09$0.09$0.09
Q2 20171$0.06$0.06$0.06
Q3 20171$0.06$0.06$0.06
Q4 20171$0.03$0.03$0.03
Q1 20181$0.12$0.12$0.12
Q2 20181$0.11$0.11$0.11
Q3 20181$0.11$0.11$0.11
Q4 20181$0.11$0.11$0.11
(Data provided by Zacks Investment Research)


Dividend History by Quarter for Luminex (NASDAQ:LMNX)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Luminex (NASDAQ:LMNX)
Insider Ownership Percentage: 6.90%
Institutional Ownership Percentage: 79.45%
Insider Trades by Quarter for Luminex (NASDAQ:LMNX)
Institutional Ownership by Quarter for Luminex (NASDAQ:LMNX)
Insider Trades by Quarter for Luminex (NASDAQ:LMNX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/18/2017G Walter Loewenbaum IIDirectorSell25,000$20.80$520,000.00View SEC Filing  
1/26/2017G Walter Loewenbaum IIDirectorSell20,000$19.75$395,000.00View SEC Filing  
1/19/2017G Walter Loewenbaum IIDirectorSell20,000$19.82$396,400.00View SEC Filing  
1/12/2017G Walter Loewenbaum IIDirectorSell20,000$20.43$408,600.00View SEC Filing  
1/5/2017G Walter Loewenbaum IIDirectorSell20,000$20.32$406,400.00View SEC Filing  
12/29/2016G Walter Loewenbaum IIDirectorSell20,000$20.27$405,400.00View SEC Filing  
11/28/2016G Walter Loewenbaum IIDirectorSell50,000$20.57$1,028,500.00View SEC Filing  
11/15/2016Kevin M McnamaraDirectorSell12,000$21.03$252,360.00View SEC Filing  
11/3/2016Harriss T. CurrieSVPBuy4,100$18.20$74,620.00View SEC Filing  
11/3/2016Nachum ShamirCEOBuy6,000$18.22$109,320.00View SEC Filing  
1/4/2016G Walter Loewenbaum IIDirectorSell41,056$20.53$842,879.68View SEC Filing  
12/31/2015G Walter Loewenbaum IIDirectorSell18,944$21.65$410,137.60View SEC Filing  
12/16/2015Russell W. BradleyCMOSell6,514$22.75$148,193.50View SEC Filing  
5/28/2015Nachum ShamirCEOBuy6,000$16.73$100,380.00View SEC Filing  
5/27/2015G Walter Loewenbaum IIDirectorBuy38,966$16.71$651,121.86View SEC Filing  
2/5/2015Fred C Goad JrDirectorSell25,000$15.46$386,500.00View SEC Filing  
10/8/2014Russell W BradleySVPSell5,000$20.50$102,500.00View SEC Filing  
5/15/2014Patrick BalthropCEOSell70,000$17.69$1,238,300.00View SEC Filing  
5/12/2014Kevin McnamaraDirectorSell5,000$17.95$89,750.00View SEC Filing  
5/9/2014Jim KeverDirectorSell5,000$17.52$87,600.00View SEC Filing  
5/7/2014Patrick BalthropCEOSell32,575$17.63$574,297.25View SEC Filing  
5/6/2014Patrick BalthropCEOSell60,000$18.28$1,096,800.00View SEC Filing  
5/2/2014Fred Goad, Jr.DirectorSell50,000$18.86$943,000.00View SEC Filing  
5/2/2014Patrick BalthropCEOSell55,000$19.05$1,047,750.00View SEC Filing  
5/1/2014David ReiterSVPSell15,000$19.09$286,350.00View SEC Filing  
5/1/2014Harriss CurrieCFOSell11,000$19.08$209,880.00View SEC Filing  
9/23/2013Harriss CurrieCFOSell30,000$19.88$596,400.00View SEC Filing  
9/17/2013Harriss CurrieCFOSell30,000$19.87$596,100.00View SEC Filing  
9/13/2013Michael PintekSVPSell3,000$20.00$60,000.00View SEC Filing  
8/30/2013G Walter Loewenbaum IIDirectorBuy6,034$20.62$124,421.08View SEC Filing  
8/28/2013G Walter Loewenbaum IIDirectorBuy20,000$20.76$415,200.00View SEC Filing  
8/16/2013Timothy DehneVPSell32,297$20.66$667,256.02View SEC Filing  
8/15/2013G Walter Loewenbaum IIDirectorBuy10,000$20.82$208,200.00View SEC Filing  
8/14/2013Timothy DehneVPSell1,793$21.21$38,029.53View SEC Filing  
8/9/2013G Walter Loewenbaum IIDirectorBuy4,600$21.17$97,382.00View SEC Filing  
8/2/2013G Walter Loewenbaum IIDirectorBuy27,000$20.01$540,270.00View SEC Filing  
8/2/2013Patrick J BalthropCEOSell68,048$20.01$1,361,640.48View SEC Filing  
8/1/2013David S ReiterSVPSell15,000$20.00$300,000.00View SEC Filing  
8/1/2013Thomas W EricksonDirectorSell20,000$20.00$400,000.00View SEC Filing  
5/24/2013Fred C Goad JrDirectorBuy11,250$18.25$205,312.50View SEC Filing  
5/17/2013G Walter Loewenbaum IIDirectorBuy13,000$18.37$238,810.00View SEC Filing  
5/16/2013Fred C Goad JrDirectorBuy8,000$18.18$145,440.00View SEC Filing  
5/15/2013G Walter Loewenbaum IIDirectorBuy39,500$18.32$723,640.00View SEC Filing  
5/10/2013David S ReiterSVPSell10,000$18.26$182,600.00View SEC Filing  
5/10/2013G Walter Loewenbaum IIDirectorBuy19,000$18.13$344,470.00View SEC Filing  
5/9/2013G Walter Loewenbaum IIDirectorBuy28,300$17.21$487,043.00View SEC Filing  
5/7/2013G Walter Loewenbaum IIDirectorBuy64,935$17.17$1,114,933.95View SEC Filing  
5/3/2013G Walter Loewenbaum IIDirectorBuy24,765$17.02$421,500.30View SEC Filing  
9/4/2012David S ReiterVPSell10,000$20.00$200,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Luminex (NASDAQ:LMNX)
Latest Headlines for Luminex (NASDAQ:LMNX)
DateHeadline logoLuminex Co. (LMNX) Upgraded by TheStreet to "B-" - May 23 at 5:34 PM logoBruker Corp (BRKR) at 52-Week High: What's Driving the Stock? - May 23 at 10:43 AM logoIDEXX Laboratories (IDXX) Raised to Buy on Solid Prospects - May 23 at 10:43 AM logoHologic (HOLX) Poised on Balanced Growth Amid Currency Woes - May 23 at 10:43 AM logoG Walter Loewenbaum II Sells 25,000 Shares of Luminex Co. (LMNX) Stock - May 22 at 4:29 PM logoIntuitive Surgical at 52-Week High: What's Driving the Stock? - May 22 at 10:20 AM logoLuminex Co. (LMNX) Receives Consensus Recommendation of "Hold" from Brokerages - May 19 at 12:52 PM logoHalyard Health Announces New Drainage System, Stock Down - May 18 at 8:54 AM logoGenomic Health's (GHDX) Oncotype DX GPS Test Data Positive - May 16 at 10:43 AM logoCR Bard (BCR) Hits a 52-Week High: What's Driving the Stock? - May 15 at 10:35 AM logoLuminex Co. (LMNX) Expected to Post Quarterly Sales of $75.18 Million - May 14 at 9:24 AM logo$0.08 EPS Expected for Luminex Co. (LMNX) This Quarter - May 12 at 2:16 PM logoLuminex Co. (LMNX) Rating Increased to Hold at ValuEngine - May 11 at 11:28 PM logoZacks Investment Research Upgrades Luminex Co. (LMNX) to "Strong-Buy" - May 4 at 1:54 PM logoQ2 2017 Earnings Forecast for Luminex Co. (LMNX) Issued By Jefferies Group - May 4 at 12:34 PM logoLuminex (LMNX) Given Daily News Sentiment Rating of 0.22 - May 3 at 8:56 PM logoLuminex Corporation Receives FDA Clearance for ARIES Bordetella Assay - May 3 at 5:25 PM logoLuminex Co. (LMNX) to Post FY2018 Earnings of $0.99 Per Share, William Blair Forecasts - May 3 at 5:14 PM logoQ3 2017 Earnings Forecast for Luminex Co. (LMNX) Issued By Jefferies Group - May 3 at 10:54 AM logoLuminex Co. (LMNX) Given Hold Rating at Jefferies Group LLC - May 2 at 7:46 PM logoEdited Transcript of LMNX earnings conference call or presentation 1-May-17 8:30pm GMT - May 2 at 12:36 PM logoBiotech Movers: Luminex, Exelixis, AMAG Pharmaceuticals - May 2 at 12:36 PM logoLuminex Co. (LMNX) Issues Earnings Results, Beats Expectations By $0.12 EPS - May 1 at 11:38 PM logoLuminex Corporation Reports Record First Quarter 2017 Financial Results; Raises 2017 Financial Guidance - May 1 at 5:22 PM logoLuminex beats Street 1Q forecasts - May 1 at 5:22 PM logoVery Positive News Coverage Extremely Likely to Impact Luminex (LMNX) Share Price - April 30 at 9:26 AM logoLuminex Corporation To Present At The Deutsche Bank 42nd Annual Health Care Conference - April 26 at 7:02 PM logoFavorable Media Coverage Extremely Likely to Impact Luminex (LMNX) Share Price - April 26 at 2:36 PM logoLuminex Corp. breached its 50 day moving average in a Bearish Manner : LMNX-US : April 24, 2017 - April 24 at 4:00 PM logoLuminex Co. (LMNX) Given Consensus Rating of "Hold" by Brokerages - April 24 at 2:50 PM logoSomewhat Negative Press Coverage Very Likely to Impact Luminex (LMNX) Stock Price - April 23 at 4:47 PM logoZacks: Brokerages Expect Luminex Co. (LMNX) Will Post Quarterly Sales of $73.99 Million - April 23 at 8:15 AM logo Brokerages Expect Luminex Co. (LMNX) Will Post Earnings of $0.08 Per Share - April 21 at 9:10 PM logoLuminex Corporation To Present At Bank Of America Merrill Lynch 2017 Health Care Conference - April 20 at 10:20 AM logoCritical News Coverage Likely to Impact Luminex (LMNX) Stock Price - April 20 at 8:45 AM logoLuminex Corp. – Value Analysis (NASDAQ:LMNX) : April 17, 2017 - April 17 at 5:38 PM logoLuminex Co. (LMNX) Cut to Sell at Zacks Investment Research - April 17 at 1:50 PM logoLuminex (LMNX) Receives Coverage Optimism Score of 0.40 - April 16 at 12:37 PM logoLuminex Co. (LMNX) Sees Significant Decrease in Short Interest - April 13 at 6:18 PM logoLuminex Corp. breached its 50 day moving average in a Bearish Manner : LMNX-US : April 13, 2017 - April 13 at 9:13 AM logoLuminex Corporation First Quarter Earnings Release Scheduled for May 1, 2017 - April 10 at 5:55 PM logoLuminex Co. (LMNX) Lowered to Sell at Zacks Investment Research - April 10 at 3:53 PM logoLuminex Co. (LMNX) Upgraded to Hold by Zacks Investment Research - April 8 at 6:09 PM logoLUMINEX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits - March 31 at 9:55 AM logoLuminex Co. (LMNX) Given Consensus Rating of "Hold" by Analysts - March 29 at 2:31 PM logoLuminex Co. (LMNX) Cut to C+ at TheStreet - March 13 at 5:57 PM logoLuminex (LMNX) Down 4.4% Since Earnings Report: Can It Rebound? - March 9 at 8:56 AM logoLUMINEX CORP Financials - March 2 at 6:33 PM logoLuminex Corporation To Present At The Barclays Global Healthcare Conference - March 1 at 5:58 PM logoLUMINEX CORP Files SEC form 10-K, Annual Report - February 24 at 7:32 PM



Luminex (LMNX) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by Staff